Novartis’ generics chief stepped down after the Swiss drugmaker sold parts of the business and initiated an 18-month revamp, fueling speculation about an eventual spin-off or sale.
FDA Commissioner Scott Gottlieb plans to step down in April 2019, a sudden resignation that calls into question how the regulatory agency will handle issues such as surging e-cigarette use among teens and efforts to increase competition in prescription drugs.
Chief Commercial Officer Steven Hoerter resigned his role at Agios Pharmaceuticals to accept a role as chief executive officer at an oncology-focused biotechnology company.
Morris Plains, N.J.-based Immunomedics announced that the company’s president, chief executive officer and board member, Michael Pehl, was stepping down for personal reasons.
Shares of Editas Medicine were down nearly 20 percent after CEO Katrine Bosley abruptly announced her decision to resign from her role at the company effective March 1, 2019.
Roche diagnostics head Roland Diggelmann is resigning as of Sept. 30, ending a 10-year stint at the Swiss drugmaker.
Scott Smith, Celgene’s chief operating officer, abruptly resigned as his decision to leave appears to be prompted by a restructuring of the company’s executive team.
Dr. Brenda Fitzgerald resigned her post as director of the U.S. Centers for Disease Control and Prevention over financial conflicts of interest, the U.S. Department of Health and Human Services (HHS) said.
Juniper Pharmaceuticals, after a strategic evaluation, decided to prioritize its resources on the company’s core businesses of Crinone progesterone gel and Juniper Pharma Services. As a result of the changes, Juniper plans to lay off 8 percent of its staff, mostly in the new product research-and-development areas.
One day after the abrupt resignation of Chief Executive Officer Uli Hacksell, Cerecor Inc. announced that the company was divesting a drug therapy for major depressive order to Janssen Pharmaceuticals for up to $45 million.